Fulgent Genetics Forecasts $330M-$340M Revenue for 2026 Amid Billing Transition Impact
Fulgent Genetics (NASDAQ: FLGT) has projected revenue of between $330 million and $340 million for the year 2026, according to management insights from its Q2 earnings call. The company's CEO, Ming Hsieh, noted that a transition in billing processes is contributing to lower collection rates at present. Despite this challenge, Fulgent remains focused on advancing its therapeutic pipeline. A key milestone was highlighted during the call: Phase II trial data for FID-007 showed encouraging results in treating recurrent or metastatic conditions. This development underscores the company's ongoing efforts to expand beyond diagnostics into therapeutics and could influence investor sentiment regarding long-term growth potential.
Tickers: $FLGT
Topics: biotech pharmaceuticals therapeutics